Taylor, Cottrill, Erickson & Associates, Inc. Catalyst Pharmaceuticals, Inc. Transaction History

Taylor, Cottrill, Erickson & Associates, Inc.

$340 Million
Q1 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2019 Jan 14, 2020	SELL	$3.67 - $5.7 $36,700 - $57,000	-10,000 Closed	0 $0
Q4 2018 Jan 29, 2019	BUY	$1.92 - $3.62 $19,200 - $36,200	10,000 New	10,000 $19,000

Others Institutions Holding CPRX

# of Institutions

279

Shares Held

95.8M

Call Options Held

40.6K

Put Options Held

67.2K

Black Rock Inc. New York, NY

17.7M
Shares

$274 Million
0.01% of portfolio
Deerfield Management Company, L.P. (Series C) New York, NY

9.13M
Shares

$141 Million
3.01% of portfolio
State Street Corp Boston, MA

8.15M
Shares

$126 Million
0.01% of portfolio
Vanguard Group Inc Valley Forge, PA

7.98M
Shares

$123 Million
0.0% of portfolio
Dimensional Fund Advisors LP Austin, TX

2.74M
Shares

$42.3 Million
0.01% of portfolio

View Full List

About CATALYST PHARMACEUTICALS, INC.

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $1.59B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

More about CPRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Taylor, Cottrill, Erickson & Associates, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Taylor, Cottrill, Erickson & Associates, Inc. with notifications on news.

Account